CASTLE BIOSCIENCES INCCSTLEarnings & Financial Report
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
Revenue
$87.0M
Gross Profit
$68.7M
Operating Profit
$-3.8M
Net Profit
N/A
Gross Margin
79.0%
Operating Margin
-4.4%
Net Margin
N/A
YoY Growth
0.8%
EPS
$-0.06
CASTLE BIOSCIENCES INC Q4 FY2025 Financial Summary
CASTLE BIOSCIENCES INC reported revenue of $87.0M (up 0.8% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $18.3M, operating expenses totaled $72.5M.
Key Financial Metrics
| Total Revenue | $87.0M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 79.0% |
| Operating Margin | -4.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
CASTLE BIOSCIENCES INC Q4 FY2025 revenue of $87.0M breaks down across 2 segments, led by Dermatologic at $48.6M (55.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Dermatologic | $48.6M | 55.8% |
| Non Dermatologic | $38.4M | 44.2% |
CASTLE BIOSCIENCES INC Revenue by Segment — Quarterly Trend
CASTLE BIOSCIENCES INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Dermatologic and Non Dermatologic) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Dermatologic | — | $48.6M | $48.5M | $56.3M |
| Non Dermatologic | — | $38.4M | $34.5M | $29.9M |
CASTLE BIOSCIENCES INC Annual Revenue by Year
CASTLE BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $344.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $344.2M |
| 2024 | $332.1M |
| 2023 | $219.8M |
| 2022 | $137.0M |
CASTLE BIOSCIENCES INC Quarterly Revenue & Net Profit History
CASTLE BIOSCIENCES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $83.7M | -4.9% | $-14.5M | -17.4% |
| Q4 FY2025 | $87.0M | +0.8% | N/A | N/A |
| Q3 FY2025 | $83.0M | -3.2% | $-501.0K | -0.6% |
| Q2 FY2025 | $86.2M | -0.9% | $4.5M | 5.2% |
| Q1 FY2025 | $88.0M | +20.6% | $-25.8M | -29.4% |
| Q4 FY2024 | $86.3M | +30.5% | N/A | N/A |
| Q3 FY2024 | $85.8M | +39.5% | $2.3M | 2.6% |
| Q2 FY2024 | $87.0M | +73.5% | $8.9M | 10.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.0M | $85.8M | $86.3M | $88.0M | $86.2M | $83.0M | $87.0M | $83.7M |
| YoY Growth | 73.5% | 39.5% | 30.5% | 20.6% | -0.9% | -3.2% | 0.8% | -4.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $487.3M | $514.6M | $531.2M | $501.7M | $544.7M | $562.8M | $578.6M | $547.8M |
| Liabilities | $63.4M | $73.5M | $75.4M | $61.4M | $89.4M | $95.7M | $107.7M | $86.4M |
| Equity | $423.9M | $441.1M | $455.8M | $440.3M | $455.4M | $467.0M | $470.9M | $461.4M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $24.0M | $23.3M | $24.4M | $-6.0M | $20.8M | $22.6M | $26.9M | $-22.1M |